Lauren Rose1, Kurt W Prins1, Stephen L Archer2, Marc Pritzker1, E Kenneth Weir1, Jeffrey R Misialek1, Thenappan Thenappan3. 1. Cardiovascular Division, University of Minnesota Medical School, Minneapolis, Minnesota, USA. 2. Department of Medicine, Queen's University, Kingston, Ontario, Canada. 3. Cardiovascular Division, University of Minnesota Medical School, Minneapolis, Minnesota, USA. Electronic address: tthenapp@umn.edu.
Abstract
BACKGROUND: Patients with pulmonary hypertension (PH) due to chronic lung disease (Group 3 PH) have poor long-term outcomes. However, predictors of survival in Group 3 PH are not well described. METHODS: We performed a cohort study of Group 3 PH patients (n = 143; mean age 65 ± 12 years, 52% female) evaluated at the University of Minnesota. The Kaplan-Meier method and Cox regression analysis were used to assess survival and predictors of mortality, respectively. The clinical characteristics and survival were compared in patients categorized by PH severity based on the World Health Organization (WHO) classification and lung disease etiology. RESULTS: After a median follow-up of 1.4 years, there were 69 (48%) deaths. The 1-, 3-, and 5-year survival rates were 79%, 48%, and 31%. Age, coronary artery disease, atrial fibrillation, Charlson comorbidity index, serum N-terminal pro‒brain natriuretic peptide (NT-proBNP), creatinine, diffusion capacity of carbon monoxide (DLCO), total lung capacity, left ventricular ejection fraction, right atrial and right ventricular enlargement on echocardiography, cardiac index, and pulmonary vascular resistance (PVR) were univariate predictors of survival. On multivariable analysis, DLCO was the only predictor of mortality (adjusted hazard ratio [HR] for every 10% decrease in predicted value: 1.31 [95% confidence interval 1.12 to 1.47]; p = 0.003). The 1-/5-year survival by tertiles of DLCO was 84%/56%, 82%/44%, and 63%/14% (p = 0.01), respectively. On receiver-operating characteristic curve analysis, DLCO <32% of predicted had the highest sensitivity and specificity for predicting survival. The 1- and 5-year survival in patients with a DLCO ≥32% predicted was 84% and 60% vs 68% and 13% in patients with a DLCO <32% predicted (adjusted HR: 2.5 [95% confidence interval 1.3 to 5.0]; p = 0.007). Lung volumes and DLCO were not related, but higher PVR was strongly associated with reduced DLCO. There was increased mortality in interstitial lung disease‒PH as compared with chronic obstructive pulmonary disease‒PH, but PH severity based on the WHO classification did not alter survival. CONCLUSIONS: Low DLCO is a predictor of mortality and should be used to risk-stratify Group 3 PH patients.
BACKGROUND:Patients with pulmonary hypertension (PH) due to chronic lung disease (Group 3 PH) have poor long-term outcomes. However, predictors of survival in Group 3 PH are not well described. METHODS: We performed a cohort study of Group 3 PH patients (n = 143; mean age 65 ± 12 years, 52% female) evaluated at the University of Minnesota. The Kaplan-Meier method and Cox regression analysis were used to assess survival and predictors of mortality, respectively. The clinical characteristics and survival were compared in patients categorized by PH severity based on the World Health Organization (WHO) classification and lung disease etiology. RESULTS: After a median follow-up of 1.4 years, there were 69 (48%) deaths. The 1-, 3-, and 5-year survival rates were 79%, 48%, and 31%. Age, coronary artery disease, atrial fibrillation, Charlson comorbidity index, serum N-terminal pro‒brain natriuretic peptide (NT-proBNP), creatinine, diffusion capacity of carbon monoxide (DLCO), total lung capacity, left ventricular ejection fraction, right atrial and right ventricular enlargement on echocardiography, cardiac index, and pulmonary vascular resistance (PVR) were univariate predictors of survival. On multivariable analysis, DLCO was the only predictor of mortality (adjusted hazard ratio [HR] for every 10% decrease in predicted value: 1.31 [95% confidence interval 1.12 to 1.47]; p = 0.003). The 1-/5-year survival by tertiles of DLCO was 84%/56%, 82%/44%, and 63%/14% (p = 0.01), respectively. On receiver-operating characteristic curve analysis, DLCO <32% of predicted had the highest sensitivity and specificity for predicting survival. The 1- and 5-year survival in patients with a DLCO ≥32% predicted was 84% and 60% vs 68% and 13% in patients with a DLCO <32% predicted (adjusted HR: 2.5 [95% confidence interval 1.3 to 5.0]; p = 0.007). Lung volumes and DLCO were not related, but higher PVR was strongly associated with reduced DLCO. There was increased mortality in interstitial lung disease‒PH as compared with chronic obstructive pulmonary disease‒PH, but PH severity based on the WHO classification did not alter survival. CONCLUSIONS: Low DLCO is a predictor of mortality and should be used to risk-stratify Group 3 PH patients.
Authors: Lawrence G Rudski; Wyman W Lai; Jonathan Afilalo; Lanqi Hua; Mark D Handschumacher; Krishnaswamy Chandrasekaran; Scott D Solomon; Eric K Louie; Nelson B Schiller Journal: J Am Soc Echocardiogr Date: 2010-07 Impact factor: 5.251
Authors: Srijoy Mahapatra; Rick A Nishimura; Paul Sorajja; Stephen Cha; Michael D McGoon Journal: J Am Coll Cardiol Date: 2006-01-26 Impact factor: 24.094
Authors: Kurt W Prins; Lauren Rose; Stephen L Archer; Marc Pritzker; E Kenneth Weir; Felipe Kazmirczak; Jeffrey R Misialek; Thenappan Thenappan Journal: Am J Respir Crit Care Med Date: 2018-06-01 Impact factor: 21.405
Authors: Henning Gall; Janine F Felix; Franziska K Schneck; Katrin Milger; Natascha Sommer; Robert Voswinckel; Oscar H Franco; Albert Hofman; Ralph T Schermuly; Norbert Weissmann; Friedrich Grimminger; Werner Seeger; Hossein A Ghofrani Journal: J Heart Lung Transplant Date: 2017-02-17 Impact factor: 10.247
Authors: Louis J Vuga; Neil R Aggarwal; Lora A Reineck; Roya Kalantari; Koyeli Banerjee; James Kiley Journal: Chest Date: 2019-05-20 Impact factor: 9.410
Authors: Daniel P Cook; Meng Xu; Victoria L Martucci; Jeffrey S Annis; Melinda C Aldrich; Anna R Hemnes; Evan L Brittain Journal: Pulm Circ Date: 2022-01-03 Impact factor: 2.886
Authors: Aparna Balasubramanian; Todd M Kolb; Rachel L Damico; Paul M Hassoun; Meredith C McCormack; Stephen C Mathai Journal: Chest Date: 2020-03-14 Impact factor: 9.410
Authors: Jasmine Tatah; Jennifer L Keen; Sasha Z Prisco; Marc Pritzker; Thenappan Thenappan; Kurt W Prins Journal: Chest Date: 2021-08-02 Impact factor: 9.410
Authors: Kurt W Prins; Lauren Rose; Stephen L Archer; Marc Pritzker; E Kenneth Weir; Matthew D Olson; Thenappan Thenappan Journal: J Am Heart Assoc Date: 2019-01-22 Impact factor: 5.501
Authors: Andrew J Synn; Wenyuan Li; Gary M Hunninghake; George R Washko; Raúl San José Estépar; George T O'Connor; Cyrus A Kholdani; Robert W Hallowell; Alexander A Bankier; Murray A Mittleman; Mary B Rice Journal: Chest Date: 2020-08-14 Impact factor: 9.410